Name: 5-Amino-1MQ
Brand: Amino Club
SKU: 5-Amino-1MQ - 50MG
Availability: InStock
Rating: 4.8 (27 reviews)

5-Amino-1MQ | 99%+ Pure Peptide | Amino Club | Amino Club

Frequently Asked Questions

Common questions about 5-Amino-1MQ research

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in the fat tissue of obese individuals. NNMT depletes both NAD+ and SAM (the universal methyl donor), promoting fat storage. By selectively blocking NNMT with an IC50 of ~1.2 μM, 5-Amino-1MQ preserves NAD+ for energy metabolism and suppresses lipogenesis (fat creation). Unlike GLP-1 receptor agonists, it works through metabolic pathways rather than appetite suppression.

No. 5-Amino-1MQ is a small molecule quinolinium derivative, not a peptide. It has a molecular weight of just 159.21 g/mol (compared to thousands for peptides). However, it is commonly researched alongside peptide-based metabolic compounds due to its complementary mechanism of action targeting the NAD+/NNMT axis.

In diet-induced obese mice, 11 days of treatment produced 5.1% body weight loss (vs 1.4% gain in controls), 35% reduction in white adipose tissue, and 30% reduction in cholesterol — all without affecting food intake. A 2024 study confirmed dose-dependent improvements in glucose tolerance, insulin sensitivity, and hepatic steatosis over 28 days. Separately, treatment in aged mice nearly doubled regenerating muscle fiber size and improved muscle strength by ~70%.

Pharmacokinetic studies in rats demonstrated 38.4% oral bioavailability with an oral half-life of 6.9 hours and peak plasma concentration of 2,252 ng/mL. High passive membrane permeability and minimal efflux support oral administration viability. However, no human oral dosing has been studied.

Preclinical data is favorable: no cytotoxicity up to 100 μM in cell culture, no genotoxicity in standard assays, and no adverse effects at 60 mg/kg/day for up to 28 days in mice. The compound is highly selective for NNMT with no off-target inhibition of related enzymes. However, no human safety data exists as no clinical trials have been conducted.

They work through completely different mechanisms. GLP-1 agonists (semaglutide, tirzepatide) primarily suppress appetite through receptor activation, while 5-Amino-1MQ increases metabolic expenditure through NNMT inhibition without affecting food intake. GLP-1 drugs are FDA-approved with extensive human clinical trial data. 5-Amino-1MQ remains preclinical with animal data only. They target different pathways and could theoretically complement each other, though combination studies have not been conducted.

5-Amino-1MQ is not approved for human use by the FDA or any regulatory authority. No clinical trials are registered on ClinicalTrials.gov, and no IND application has been publicly reported. All research originates primarily from the Watowich/Neelakantan laboratory at the University of Texas Medical Branch. It is classified as a research chemical only.

5-Amino-1MQ

Frequently Researched Together

NAD+

Blocking the Fat Switch

NNMT Inhibition

NAD+ Salvage Pathway

Polyamine Flux Pathway

Why NNMT Matters for Fat

Weight Loss Without Appetite Suppression

Body Weight Change in DIO Mice (11 Days)

Key Research Outcomes

Fat Mass Reduction: NNMTi vs Diet Alone

28-Day Dose-Response Study (2024)

Muscle Regeneration in Aging

Hepatic Steatosis Improvement

Microbiome Modulation

Anti-Proliferative Activity

No observed toxicity

No genotoxicity

No appetite changes

Injection site reactions

Highly Selective Action

Preclinical Safety Summary

Important Considerations

💡Researcher Notes

What Is 5-Amino-1MQ?

Stability Information

Where It Stands

What is 5-Amino-1MQ and how does it work?

Is 5-Amino-1MQ a peptide?

What does the preclinical research show?

Can 5-Amino-1MQ be taken orally?

What is the safety profile?

How does 5-Amino-1MQ compare to GLP-1 drugs like Ozempic?

What is the regulatory status?

Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase

Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice

Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle

Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice

Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies

Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells

Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice

Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction

⚠️Important Research Notice

All the research peptides you need, with the peace of mind and research community at your fingertips.

Stay Updated with Amino Club

Frequently Researched Together

NAD+

Researcher Notes